Physician profile
Joel Herring
NPI 1831286699
$11,670.37
in general payments reported to CMS, 2019-2025
15 companies · $292 in 2025
The $292 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $617 · 2021: $903 · 2022: $7,546 · 2023: $977 · 2024: $465 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,735.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $8,953.13 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $943.92 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $565.80 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $261.36 | 2023-2024 | Stellaris, Xipere |
| Genentech USA, INC. | $189.57 | 2022-2023 | Vabysmo |
| Biogen, INC. | $157.89 | 2023-2024 | Byooviz |
| Astellas Pharma US INC | $125.70 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $125.00 | 2023 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $98.06 | 2019 | |
| Optos, INC. | $67.56 | 2019 | |
| Alimera Sciences, INC. | $58.32 | 2022 | |
| Coherus Oncology, INC. | $43.15 | 2023-2024 | |
| Carl Zeiss Meditec, INC. | $38.44 | 2020 | |
| Mallinckrodt Hospital Products INC. | $25.80 | 2020 | |
| Amgen INC. | $16.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$33,333.32 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Herring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.